about
An Introduction to Health Care Administrative Data.Initial uptake of the Ontario Pharmacy Smoking Cessation Program: Descriptive analysis over 2 years.Osteoporosis management and fractures in the Métis of Ontario, Canada.Factors affecting the delivery of community pharmacist-led medication reviews: evidence from the MedsCheck annual service in Ontario.A population-based matched cohort study examining the mortality and costs of patients with community-onset Clostridium difficile infection identified using emergency department visits and hospital admissionsUptake of the MedsCheck annual medication review service in Ontario community pharmacies between 2007 and 2013Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.The economic impact of Clostridium difficile infection: a systematic review.Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendations.Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network meta-analysis.Diffusion of Innovations model helps interpret the comparative uptake of two methodological innovations: co-authorship network analysis and recommendations for the integration of novel methods in practice.Cost-of-illness studies in chronic ulcers: a systematic review.Urban-rural differences in the uptake of new oral bisphosphonate formulations.Performance of the disease risk score in a cohort study with policy-induced selection bias.The Economic Burden of Hospital-Acquired Clostridium difficile Infection: A Population-Based Matched Cohort Study.The three-year incidence of fracture in chronic kidney disease.Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses.Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study.Impact of Timing of Methadone Initiation on Perinatal Outcomes Following Delivery Among Pregnant Women on Methadone Maintenance Therapy in OntarioComparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis—reply to Pazianas and AbrahamsenIncreased risk of all-cause mortality associated with domperidone use in Parkinson's patients: a population-based cohort study in the UKThe lifetime cost of spinal cord injury in Ontario, Canada: A population-based study from the perspective of the public health care payerHistory and publication trends in the diffusion and early uptake of indirect comparison meta-analytic methods to study drugs: animated coauthorship networks over timeAnalysis of Trends in Insulin Utilization and Spending Across Canada From 2010 to 2015Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and RestartDesign choices for observational studies of the effect of exposure on disease incidenceDenosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gapTime trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changesExternal validation of clinical prediction rules for complications and mortality following Clostridioides difficile infectionFive-year refracture rates of a province-wide fracture liaison serviceDenosumab and breast cancer risk in postmenopausal women: a population-based cohort study
P50
Q30979379-4B4D1F8C-74BD-4E70-83F7-C88D892527A8Q34961922-F044C5E6-0015-4ECA-B14E-03E0F58750C5Q35547167-FB01B5D9-7302-4992-A054-DC7EBBEBFB29Q36200332-F1F746F1-3BCD-40D5-A767-20E9DC8E0F2CQ36296607-998AAD8F-B2B0-4745-9778-718C0E512D89Q37275373-E467AED8-9E95-475A-890D-36402CF73984Q38167249-3C356979-7E73-46BF-B1F6-7BAFE72E7686Q38409139-9394F6A7-6D0B-4D72-8178-BDE89D04A4BBQ38428261-527C8E1D-2FF1-408F-9107-501232F0622FQ38676353-75CD11E6-E04D-405C-909E-97B6533BC676Q38702184-1A9A7126-3A6D-4074-9C28-4459F422FF49Q39065435-B26561D3-E26A-47BD-B80B-5EC9703F067EQ39221460-664B025F-CF50-4206-8DC3-AD44A991A348Q40351348-B3C64C3D-ED25-426D-B884-EF867DB3ADA9Q40361680-19898517-9433-40AE-ACC3-0B1127BA8DC3Q42102020-F9094148-9E4E-42D9-8CD6-0E8CAF97E2A7Q44741994-BF5E21A7-8FAF-4648-9400-21A42C2BE76AQ47722324-D4E95356-4618-451E-9B01-BD8AF906B4EBQ54982067-B84422BD-AD11-4DDD-83E7-DAC33111D9CEQ57051216-2D3C4D77-2B8B-4F8A-8A99-81326620510EQ57695476-D6A76683-571D-4008-AC85-83883C329389Q64866056-64464B42-2410-4DC9-9E43-544913783094Q89164378-81AAEACE-3FBF-41D5-87C5-58FABDC6061EQ89365659-745906D1-AD38-4652-9E8D-7CE7B5E0665AQ90461222-BD5FB0E0-EC20-48BC-BCC9-5C132C413E22Q91243629-7DC9E014-04BF-43A5-858B-6E73339F3E74Q91853174-0F1DA469-FA76-49AE-ADA8-E1256836A1AEQ91977427-726543A4-A6BB-4635-8D44-8B5C9152985FQ91977431-37763381-D5B0-454D-B8E3-91A05A41B65FQ92043647-4DDF63C8-E602-4095-A367-6D0A5273906CQ92452035-2595DE14-A098-4B11-B1A7-E5BC2FC8F84BQ93016733-014DE2C7-2F19-4A28-8F6E-26C02A597C6C
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
S M Cadarette
@en
S M Cadarette
@nl
type
label
S M Cadarette
@en
S M Cadarette
@nl
prefLabel
S M Cadarette
@en
S M Cadarette
@nl
P31
P496
0000-0002-8584-9649